Neos Therapeutics, Inc. (NEOS): Gregory J Robitaille , director of Neos Therapeutics, Inc. purchased 7,442 shares on May 18, 2016. The Insider buying transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were purchased at $7.55 per share for a total value of $56,149.89 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 28, 2015, Jack W Schuler (10% owner) purchased 20,000 shares at $15.00 per share price.
Company has been under the radar of several Street Analysts.Neos Therapeutics Inc is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 29 from a previous price target of $33 . The Rating was issued on May 17, 2016.
Neos Therapeutics Inc. is a pharmaceutical company develops manufactures and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The Companys product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It manufactures and markets generic Tussionex a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie Texas.